INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of MoonLake Immunotherapeutics (MLTX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Viewpoint - A shareholder class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its product SLK and its comparison to monoclonal antibodies [1] Summary by Relevant Sections Allegations - The lawsuit claims that the defendants failed to disclose critical information about the differences between Nanobodies and monoclonal antibodies, specifically that: - SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1] - SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [1] - The supposed increased tissue penetration of SLK does not lead to improved clinical efficacy [1] - Defendants lacked a reasonable basis for their positive claims regarding SLK's superiority to monoclonal antibodies [1] Legal Information - Shareholders who purchased MoonLake shares between March 10, 2024, and September 29, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is December 15, 2025 [3]